+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Systemic Lupus Erythematosus (SLE) - Market Insights, Epidemiology, and Market Forecast - 2028

  • ID: 4436377
  • Drug Pipelines
  • November 2019
  • Region: Global
  • 234 pages
  • DelveInsight
1 of 3

FEATURED COMPANIES

  • AstraZeneca
  • Bristol-MyersSquibb
  • Eli Lilly
  • Idorsia Pharmaceuticals
  • ImmuPharma
  • Kezar Life Science
  • MORE
‘Systemic Lupus Erythematosus (SLE) - Market Insights, Epidemiology, and Market Forecast-2028' report deliver an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of Systemic Lupus Erythematosus in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, the current and forecasted market size of Systemic Lupus Erythematosus from 2017 to 2028 segmented by seven major markets.

The phenomenon of Systemic Lupus Erythematosus (SLE) is a prototypic autoimmune disease characterized by the production of antibodies to components of the cell nucleus in association with a diverse array of clinical manifestations. The primary pathological findings in patients with SLE are those of inflammation, vasculitis, immune complex deposition, and vasculopathy

According to the American College of Rheumatology, ‘Systemic lupus erythematosus, is referred to as chronic (long-term) disease that causes systemic inflammation which affects multiple organs. In addition to affecting the skin and joints, it can affect other organs in the body such as the kidneys, the tissue lining the lungs (pleura), heart (pericardium), and brain'.

Geography Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
Study Period: 2017-2028

Systemic Lupus Erythematosus - Disease Understanding and Treatment Algorithm

SLE is a disease of unknown etiology with a variety of presenting features and manifestations. The majority of the pathology in SLE is related to deposits of immune complexes in various organs, which triggers complement other mediators of inflammation. Symptoms vary from person to person, depending on what part of the body is affected, can be mild, moderate, or severe. Clinical manifestations are heterogeneous, vary as a result of the type of the disease and organ involvement of an individual. Diagnosis can be difficult because lupus mimics many other diseases; it requires clinical and serologic criteria.

Systemic Lupus Erythematosus Epidemiology

The Systemic Lupus Erythematosus epidemiology division provides insights about historical and current patient pool and forecasted trends for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders (KOL).

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Diagnosed Prevalent cases, Gender-Specific Prevalence, and Severity Specific Prevalence) scenario of Systemic Lupus Erythematosus in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017 to 2028.

According to this research, the total Diagnosed Prevalent cases of Systemic Lupus Erythematosus (SLE) in the 7MM was found to be 484,213 in 2017. The prevalence of Systemic Lupus Erythematosus in the 7MM is expected to increase during the study period of 2017-2028.

Systemic Lupus Erythematosus Drug Chapters

This segment of the Systemic Lupus Erythematosus report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

At present, the therapeutic market size of SLE in the US is mainly accounted for the management options consisting of Corticosteroids, Immunosuppressants, Antimalarials (Plaquenil) and Biologics (Rituximab, Belimumab). Nonsteroidal anti-inflammatory drugs (NSAIDs) may also be used to treat inflammation and pain.

Hydroxychloroquine (Plaquenil) and Belimumab (Benlysta) are approved therapies for the treatment of SLE in the US.

Detailed chapters of current therapies, such as Belimumab (GlaxoSmithKline) and emerging therapies, such as Anifrolumab (AstraZeneca), Lupuzor (ImmuPharma), Baricitinib (Eli Lilly), Ustekinumab (Janssen Pharmaceutical), Atacicept (Merck), Dapirolizumab pegol (UCB Pharma/ Biogen), CC-220 (Celgene), IFNa KINOID (Neovacs), ILT-101 (Iltoo Pharma), BIIB059 (Biogen), Lulizumab (Bristol-MyersSquibb), Obexelimab (Xencor), KZR-616 (Kezar Life Sciences), Cenerimod (Idorsia Pharmaceuticals) and others have also been provided in the report.

Systemic Lupus Erythematosus Market Outlook

The Systemic Lupus Erythematosus market outlook of the report helps to build a detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

According to this research, the market for Systemic Lupus Erythematosus in 7MM was found to be approximately USD 1,447.35 million in 2017.

Systemic Lupus Erythematosus market size in the United States accounted for 71% of the total market in 2017. The US led the market in 2017, followed by the EU5 and Japan, respectively. Due to the high prevalence of this disease in the region, the Systemic Lupus Erythematosus treatment market in the US is expected to dominate the market during the forecast period (2019-2028).

Systemic Lupus Erythematosus Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017 to 2028. The analysis covers market uptake by drugs; patient uptake by therapies, and sales of each drug.

The dynamics of Systemic Lupus Erythematosus market is anticipated to change in the coming years owing to the expected launch of emerging therapies, such as, Belimumab (GlaxoSmithKline) and emerging therapies, such as Anifrolumab (AstraZeneca), Lupuzor (ImmuPharma), Baricitinib (Eli Lilly), Ustekinumab (Janssen Pharmaceutical), Atacicept (Merck), Dapirolizumab pegol (UCB Pharma/ Biogen), CC-220 (Celgene), IFNa KINOID (Neovacs), ILT-101 (Iltoo Pharma), BIIB059 (Biogen), Lulizumab (Bristol-MyersSquibb), Obexelimab (Xencor), KZR-616 (Kezar Life Sciences), Cenerimod (Idorsia Pharmaceuticals)), and others in the Systemic Lupus Erythematosus market by 2028.

Systemic Lupus Erythematosus Report Insights
  • Patient Population of Systemic Lupus Erythematosus
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies
Systemic Lupus Erythematosus Report Key Strengths
  • 10-Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition
Systemic Lupus Erythematosus Report Assessment
  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers
Key Benefits
  • This report will help to develop Business Strategies by understanding the trends shaping and driving Systemic Lupus Erythematosus market
  • Organize sales and marketing efforts by identifying the best opportunities for Systemic Lupus Erythematosus market
  • To understand the future market competition in the Systemic Lupus Erythematosus market
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AstraZeneca
  • Bristol-MyersSquibb
  • Eli Lilly
  • Idorsia Pharmaceuticals
  • ImmuPharma
  • Kezar Life Science
  • MORE
1. Key Insights

2. Systemic Lupus Erythematosus (SLE): Market Overview at a Glance
2.1. Total Market Share (%) Distribution of SLE in 2017
2.2. Total Market Share (%) Distribution of SLE in 2028

3. Disease Background and Overview: Systemic Lupus Erythematosus (SLE)
3.1. Introduction
3.2. Risk Factors
3.3. Causes
3.4. Symptoms
3.5. Clinical Manifestation
3.6. Pathogenesis
3.7. Biologics and Biomarkers in the Treatment and Diagnosis of SLE
3.8. Diagnosis
3.8.1. Recent classification of SLE

4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Population and Forecast Parameters
4.3. Total Diagnosed Prevalent cases of SLE in 7MM
4.4. United States
4.4.1. Assumptions and Rationale
4.4.2. Total Diagnosed Prevalent cases of SLE in the US
4.4.3. Gender Specific cases of SLE in the US
4.4.4. Severity Specific cases of SLE in the US
4.5. EU5
4.6. Germany
4.6.1. Assumptions and Rationale
4.6.2. Total Diagnosed Prevalent cases of SLE in Germany
4.6.3. Gender Specific cases of SLE in Germany
4.6.4. Severity Specific cases of SLE in Germany
4.7. France
4.7.1. Assumptions and Rationale
4.7.2. Total Diagnosed Prevalent cases of SLE in France
4.7.3. Gender Specific cases of SLE in France
4.7.4. Severity Specific cases of SLE in France
4.8. Italy
4.8.1. Assumptions and Rationale
4.8.2. Total Diagnosed Prevalent cases of SLE in Italy
4.8.3. Gender Specific cases of SLE in Italy
4.8.4. Severity Specific cases of SLE in Italy
4.9. Spain
4.9.1. Assumptions and Rationale
4.9.2. Total Diagnosed Prevalent cases of SLE in Spain
4.9.3. Gender Specific cases of SLE in Spain
4.9.4. Severity Specific cases of SLE in Spain
4.10. United Kingdom
4.10.1. Assumptions and Rationale
4.10.2. Total Diagnosed Prevalent cases of SLE in the UK
4.10.3. Gender Specific cases of SLE in the UK
4.10.4. Severity Specific cases of SLE in the UK
4.11. Japan
4.11.1. Assumptions and Rationale
4.11.2. Total Diagnosed Prevalent cases of SLE in Japan
4.11.3. Gender Specific cases of SLE in Japan
4.11.4. Severity Specific cases of SLE in Japan

5. Current Treatment
5.1. EULAR Recommendations

6. Unmet Needs

7. Marketed drugs
7.1. Benlysta: GlaxoSmithKline
7.1.1. Drug Description
7.1.2. Regulatory Milestones
7.1.3. Other Developmental Activities
7.1.4. Clinical Development
7.1.5. Safety and Efficacy
7.1.6. Product Profile

8. Emerging Drugs
8.1. Key Cross Competition
8.1.1. Key Cross Competition: Phase III Emerging Therapies
8.1.2. Key Cross Competition: Phase II Emerging Therapies
8.1.3. Key Cross Competition: Other Emerging Potential Therapies
8.2. Anifrolumab: AstraZeneca
8.2.1. Drug Description
8.2.2. Other Developmental Activities
8.2.3. Clinical Development
8.2.4. Safety and Efficacy
8.2.5. Product Profile
8.3. Lupuzor: Immupharma
8.3.1. Drug Description
8.3.2. Other Developmental Activities
8.3.3. Clinical Development
8.3.4. Safety and Efficacy
8.3.5. Product Profile
8.4. Baricitinib: Eli Lilly
8.4.1. Drug Description
8.4.2. Other Developmental Activities
8.4.3. Clinical Development
8.4.4. Safety and Efficacy
8.4.5. Product Profile
8.5. Stelara (ustekinumab): Janssen Pharmaceutical
8.5.1. Drug Description
8.5.2. Other Developmental Activities
8.5.3. Clinical Development
8.5.4. Safety and Efficacy
8.5.5. Product Profile
8.6. Atacicept: Merck KGaA
8.6.1. Drug Description
8.6.2. Other Developmental Activities
8.6.3. Clinical Development
8.6.4. Safety and Efficacy
8.6.5. Product Profile
8.7. ILT-101: Iltoo Pharma
8.7.1. Drug Description
8.7.2. Other Developmental Activities
8.7.3. Clinical Development
8.7.4. Safety and Efficacy
8.7.5. Product Profile
8.8. BIIB059: Biogen
8.8.1. Drug Description
8.8.2. Other Developmental Activities
8.8.3. Clinical Development
8.8.4. Safety and Efficacy
8.8.5. Product Profile
8.9. CC-220: Celgene
8.9.1. Drug Description
8.9.2. Clinical Development
8.9.3. Safety and Efficacy
8.9.4. Product Profile
8.10. Dapirolizumab pegol: UCB Pharma/ Biogen
8.10.1. Drug Description
8.10.2. Other Developmental Activities
8.10.3. Clinical Development
8.10.4. Safety and Efficacy
8.10.5. Product Profile
8.11. IFNa Kinoid: Neovacs
8.11.1. Drug Description
8.11.2. Other Developmental Activities
8.11.3. Clinical Development
8.11.4. Safety and Efficacy
8.11.5. Product Profile
8.12. ACT-334441 (Cenerimod): Idorsia Pharmaceuticals
8.12.1. Drug Description
8.12.2. Other Developmental Activities
8.12.3. Clinical Development
8.12.4. Safety and Efficacy
8.12.5. Product Profile
8.13. KZR-616: Kezar Life Sciences
8.13.1. Drug Description
8.13.2. Clinical Development
8.13.3. Safety and Efficacy
8.13.4. Product Profile
8.14. Lulizumab (BMS-931699): Bristol-Myers Squibb
8.14.1. Drug Description
8.14.2. Clinical Development
8.14.3. Safety and Efficacy
8.14.4. Product Profile
8.15. Obexelimab (XmAb5871): Xencor
8.15.1. Drug Description
8.15.2. Other Developmental Activities
8.15.3. Clinical Development
8.15.4. Safety and Efficacy
8.15.5. Product Profile

9. Other potential therapies
9.1. RSLV-132: Resolve Therapeutics
9.1.1. Drug Description
9.1.2. Other Developmental Activities
9.1.3. Clinical Development
9.1.4. Safety and Efficacy
9.1.5. Product Profile
9.2. VIB7734: VIELABIO
9.2.1. Drug Description
9.2.2. Other Developmental Activities
9.2.3. Clinical Development
9.2.4. Product Profile
9.3. Tofacitinib: Pfizer
9.3.1. Drug Description
9.3.2. Other Developmental Activities
9.3.3. Clinical Development
9.3.4. Safety and Efficacy
9.3.5. Product Profile

10. Market Size
10.1. Key Findings
10.2. Total Market Size of SLE in 7MM
10.3. Total Market Size of SLE by Therapies in 7MM

11. US: Market Outlook
11.1. Total Market size of SLE in the US
11.2. Market size of SLE by Current Therapies
11.3. Market size of SLE by Emerging Therapies

12. EU-5: Market outlook
12.1. Germany
12.1.1. Total Market size of SLE in Germany
12.1.2. Market size of SLE by Current Therapies
12.1.3. Market size of SLE by Emerging Therapies
12.2. France
12.2.1. Total Market size of SLE in France
12.2.2. Market size of SLE by Current Therapies
12.2.3. Market size of SLE by Emerging Therapies
12.3. Italy
12.3.1. Total Market size of SLE in Italy
12.3.2. Market size of SLE by Current Therapies
12.3.3. Market size of SLE by Emerging Therapies
12.4. Spain
12.4.1. Total Market size of SLE in Spain
12.4.2. Market size of SLE by Current Therapies
12.4.3. Market size of SLE by Emerging Therapies
12.5. United Kingdom
12.5.1. Total Market size SLE in the UK
12.5.2. Market size of SLE by Current Therapies
12.5.3. Market size of SLE by Emerging Therapies

13. Japan: Market Outlook
13.1. Total Market size of SLE in Japan
13.2. Market size of SLE by Current Therapies
13.3. Market size of SLE by Emerging Therapies

14. Market Drivers

15. Market Barriers

16. KOL Views

17. Appendix
17.1. Report Methodology

18. Capabilities

19. Disclaimer

20. About the Publisher

List of Tables
Table 1: Major clinical manifestations of Systemic Lupus Erythematosus (SLE)
Table 2: Summary of key pathogenic processes, cells, and molecules in SLE
Table 3: Differential Diagnosis of Systemic Lupus Erythematosus
Table 4: Diagnostic criteria for Systemic Lupus Erythematosus
Table 5: Classification criteria for Systemic Lupus Erythematosus
Table 6: Total Diagnosed Prevalent cases of SLE in 7MM (2017-2028)
Table 7: Total Diagnosed Prevalent Cases of SLE in the US (2017-2028)
Table 8: Gender -Specific Prevalent Cases of SLE in the US (2017-2028)
Table 9: Severity Specific Prevalent Cases of SLE in the US (2017-2028)
Table 10: Total Diagnosed Prevalent Cases of SLE in Germany (2017-2028)
Table 11: Gender Specific Prevalent Cases of SLE in Germany (2017-2028)
Table 12: Severity Specific Prevalent Cases of SLE in Germany (2017-2028)
Table 13: Total Diagnosed Prevalent Cases of SLE in France (2017-2028)
Table 14: Gender Specific Prevalent Cases of SLE in France (2017-2028)
Table 15: Severity Specific Prevalent Cases of SLE in France (2017-2028)
Table 16: Total Diagnosed Prevalent Cases of SLE in Italy (2017-2028)
Table 17: Gender Specific Prevalent Cases of SLE in Italy (2017-2028)
Table 18: Severity Specific Prevalent Cases of SLE in Italy (2017-2028)
Table 19: Total Diagnosed Prevalent Cases of SLE in Spain (2017-2028)
Table 20: Gender Specific Prevalent Cases of SLE in Spain (2017-2028)
Table 21: Severity Specific Prevalent Cases of SLE in Spain (2017-2028)
Table 22: Total Diagnosed Prevalent Cases of SLE in the UK (2017-2028)
Table 23: Gender Specific Prevalent Cases of SLE in the UK (2017-2028)
Table 24: Severity Specific Prevalent Cases of SLE in the UK (2017-2028)
Table 25: Total Diagnosed Prevalent Cases of SLE in Japan (2017-2028)
Table 26: Gender Specific Prevalent Cases of SLE in Japan (2017-2028)
Table 27: Severity Specific Prevalent Cases of SLE in Japan (2017-2028)
Table 28: 2019 EULAR Recommendations for the management of SLE
Table 29: Benlysta, Clinical Trial Description, 2019
Table 30: Clinical Response Rate in Patients with SLE after 52 weeks of treatment
Table 31: Key cross competition- Phase III Drugs
Table 32: Key cross competition - Phase II drugs
Table 33: Key cross competition- Other Emerging Potential Therapies
Table 34: Key cross competition- Other Potential Therapies (Cntd.)
Table 35: Anifrolumab, Clinical Trial Description, 2019
Table 36: Lupuzor, Clinical Trial Description, 2019
Table 37: Baricitinib, Clinical Trial Description, 2019
Table 38: Stelara, Clinical Trial Description, 2019
Table 39: Atacicept, Clinical Trial Description, 2019
Table 40: ILT-101, Clinical Trial Description, 2019
Table 41: BIIB059, Clinical Trial Description, 2019
Table 42: CC-220, Clinical Trial Description, 2019
Table 43: Dapirolizumab pegol, Clinical Trial Description, 2019
Table 44: IFNa Kinoid, Clinical Trial Description, 2019
Table 45: Cenerimod, Clinical Trial Description, 2019
Table 46: KZR-616, Clinical Trial Description, 2019
Table 47: BMS-931699, Clinical Trial Description, 2019
Table 48: XmAb5871, Clinical Trial Description, 2019
Table 49: RSLV-132, Clinical Trial Description, 2019
Table 50: VIB7734, Clinical Trial Description, 2019
Table 51: Tofacitinib, Clinical Trial Description, 2019
Table 52: Total Market Size of SLE in 7MM in USD Million (2017-2028)
Table 53: Total Market Size of SLE in 7MM in USD Million (2017-2028)
Table 54: Total Market size of SLE in the US (2017-2028)
Table 55: Market Size of SLE by Current Therapies in USD Million (2017-2028)
Table 56:Market Size of SLE by Emerging Therapies in USD Million (2017-2028)
Table 57: Total Market size of SLE in Germany (2017-2028)
Table 58: Market Size of SLE by Current Therapies in USD Million (2017-2028)
Table 59: Market Size of SLE by Emerging Therapies in USD Million (2017-2028)
Table 60: Market size of SLE in France (2017-2028)
Table 61: Market Size of SLE by Current Therapies in USD Million (2017-2028)
Table 62: Market Size of SLE by Emerging Therapies in USD Million (2017-2028)
Table 63: Total Market size of SLE in Italy (2017-2028)
Table 64: Market Size of SLE by Current Therapies in USD Million (2017-2028)
Table 65: Market Size of SLE by Emerging Therapies in USD Million (2017-2028)
Table 66: Total Market size of Systemic Lupus Erythematosus (SLE) in Spain (2017-2028)
Table 67: Market Size of SLE by Current Therapies in USD Million (2017-2028)
Table 68: Market Size of SLE by Emerging Therapies in USD Million (2017-2028)
Table 69: Total Market size of SLE in the UK (2017-2028)
Table 70: Market Size of SLE by Current Therapies in USD Million (2017-2028)
Table 71: Market Size of SLE by Emerging Therapies in USD Million (2017-2028)
Table 72: Total Market size of SLE in Japan (2017-2028)
Table 73: Market Size of SLE by Current Therapies in USD Million (2017-2028)
Table 74:Market Size of SLE by Emerging Therapies in USD Million (2017-2028)

List of Figures
Figure 1: Management of Systemic Lupus Erythematosus
Figure 2: Risk Factors of SLE
Figure 3: T-cell Signaling and Gene regulation in SLE
Figure 4: Role of Innate Cells (Neutrophils, Macrophages, and Dendritic Cells) in SLE
Figure 5: Algorithm for the diagnosis of Systemic Lupus Erythematosus
Figure 6: Total Diagnosed Prevalent cases of SLE in 7MM (2017-2028)
Figure 7: Total Diagnosed Prevalent Cases of SLE in the US (2017-2028)
Figure 8: Gender -Specific Cases of SLE in the US (2017-2028)
Figure 9: Severity Specific Cases of SLE in the US (2017-2028)
Figure 10: Total Diagnosed Prevalent Cases of SLE in Germany (2017-2028)
Figure 11: Gender -Specific Cases of SLE in Germany (2017-2028)
Figure 12: Severity Specific Cases of SLE in Germany (2017-2028)
Figure 13: Total Diagnosed Prevalent Cases of SLE in France (2017-2028)
Figure 14: Gender Specific Cases of SLE in France (2017-2028)
Figure 15: Severity Specific Cases of SLE in France (2017-2028)
Figure 16: Total Diagnosed Prevalent Cases of SLE in Italy (2017-2028)
Figure 17: Gender Specific Cases of SLE in Italy (2017-2028)
Figure 18: Severity Specific Cases of SLE in Italy (2017-2028)
Figure 19: Total Diagnosed Prevalent Cases of SLE in Spain (2017-2028)
Figure 20: Gender Specific Cases of SLE in Spain (2017-2028)
Figure 21: Severity Specific Cases of SLE in Spain (2017-2028)
Figure 22: Total Diagnosed Prevalent Cases of SLE in the UK (2017-2028)
Figure 23: Gender Specific Cases of SLE in the UK (2017-2028)
Figure 24: Severity Specific Cases of SLE in the UK (2017-2028)
Figure 25: Total Diagnosed Prevalent Cases of SLE in Japan (2017-2028)
Figure 26: Gender Specific Cases of SLE in Japan (2017-2028)
Figure 27: Severity Specific Cases of SLE in Japan (2017-2028)
Figure 28: Treatment of Non-renal SLE
Figure 29: Unmet need: Failure of Numerous clinical trials
Figure 30: Unmet Need: Complexity in Pathophysiology of the diseases
Figure 31: Steps to fulfill the current unmet need
Figure 32: Total Market Size of SLE in 7MM in USD Million (2017-2028)
Figure 33: Total Market Size of SLE in 7MM in USD Million (2017-2028)
Figure 34: Market size of SLE in the US (2017-2028)
Figure 35: Market Size of SLE by Current Therapies in USD Million (2017-2028)
Figure 36: Market Size of SLE by Emerging Therapies in USD Million (2017-2028)
Figure 37: Total Market size of SLE in Germany (2017-2028)
Figure 38: Market Size of SLE by Current Therapies in USD Million (2017-2028)
Figure 39: Market Size of SLE by Emerging Therapies in USD Million (2017-2028)
Figure 40: Market size of SLE in France (2017-2028)
Figure 41: Market Size of SLE by Current Therapies in USD Million (2017-2028)
Figure 42: Market Size of SLE by Emerging Therapies in USD Million (2017-2028)
Figure 43: Total Market size of SLE in Italy (2017-2028)
Figure 44: Market Size of SLE by Current Therapies in USD Million (2017-2028)
Figure 45: Market Size of SLE by Emerging Therapies in USD Million (2017-2028)
Figure 46: Total Market size of SLE in Spain (2017-2028)
Figure 47: Market Size of SLE by Current Therapies in USD Million (2017-2028)
Figure 48: Market Size of SLE by Emerging Therapies in USD Million (2017-2028)
Figure 49: Total Market size of SLE in the UK (2017-2028)
Figure 50: Market Size of SLE by Current Therapies in USD Million (2017-2028)
Figure 51: Market Size of SLE by Emerging Therapies in USD Million (2017-2028)
Figure 52: Total Market size of SLE in Japan (2017-2028)
Figure 53: Market Size of SLE by Current Therapies in USD Million (2017-2028)
Figure 54: Market Size of SLE by Emerging Therapies in USD Million (2017-2028)
Figure 55: Market Drivers
Figure 56:Market Barriers
Note: Product cover images may vary from those shown
3 of 3
  • GlaxoSmithKline
  • AstraZeneca
  • ImmuPharma
  • Eli Lilly
  • Janssen Pharmaceutical
  • Merck
  • UCB Pharma/ Biogen
  • Celgene
  • Neovacs
  • Iltoo Pharma
  • Biogen
  • Bristol-MyersSquibb
  • Xencor
  • Kezar Life Science
  • Idorsia Pharmaceuticals
Note: Product cover images may vary from those shown
Adroll
adroll